Dystonia Drugs Market - IHR Insights

Reports

📃Pages:
180

📊Tables:
92

📈Charts:
62

🌐Regions/Countries:
4 / 10

🏢Companies:
10

📨Enquiry Hours:
10

Dystonia can be referred to a movement disorder featured by involuntary muscle contractions which cause slow repetitive movements or abnormal postures. These muscle contractions result in unusual muscle movements and body postures. There are various types of dystonia affecting a single muscle, or a group of muscles or may affect muscles all over the body. The rise of the dystonia drugs market is projected to be driven by high potential in untapped, rising markets, owing to availability of developing healthcare infrastructure, rise in unmet healthcare needs, and rise in demand for advanced healthcare facilities. Additionally, surge in prevalence of dystonia and also surge in incidence of other neurological disorders having dystonia symptoms is propelling the growth of the market. This increase in incidence of dystonia, augments the demand for dystonia treatment medications which further accelerates the growth of the dystonia drugs market share. However, the huge costs incurred in the treatment of dystonia may limit the market growth. The Dystonia Drugs Market is anticipated to grow at a rate of 5.3% CAGR by 2027.

Dystonia Drugs Market by Drug Type:

Anticonvulsants drugs
Others
Dopaminergic agents
GABAergic agents

Dystonia Drugs Market by Route of Administration:

Oral
Injectable

Dystonia Drugs Market by Distribution Channel:

Hospital Pharmacies
Online Providers
Drug Stores and Retail Pharmacies

Dystonia Drugs Market by Geography:

North America
Europe
Asia Pacific
Rest of the World

The market based product type is divided into Anticonvulsants drugs, Others, Dopaminergic agents and GABAergic agents. GABAergic agents segment has the largest share in the market. The growth is ascribed to its advantages in treating dystonia, especially cervical dystonia. Moreover, the discovery of highly effective and potent GABAergic agent pharmaceuticals for treating dystonia, along with its more extensive prescription by healthcare experts, is boosting the segment’s growth in the forecasted period.

As per the market by route of administration, the market is bifurcated into Oral and Injectable. Among them the injectable segment has the substantial share in the market. This is due to the increase in innovations in parenteral dosing and increased research and development for botulinum injections. Absorption of the medication, particularly aqueous solutions, is rapid and uniform. There is a swift commencement of effect compared to the oral and subcutaneous methods.

The distribution channel segment is classified into Hospital Pharmacies, Online Providers and Drug Stores and Retail Pharmacies. The drug stores & retail pharmacies segment is accounted for the maximum share in the market. This is because of its substantial chain of distribution networks and it being the oldest and most easy channel for providing drugs to consumers. Retail pharmacists prepare and dispense drugs, advise consumers on the proper use of medications, and inform them of possible drug interactions.

In market by geographical analysis, the North America region has acquired a substantial share in the market. The surge in incidences of dystonia coupled with surge in prevalence of other neurological conditions causing dystonia in U.S. population and other major nations is the key factor for augmenting demand for dystonia drugs in North America.

The federal government influences private investment on research and development through programs which augment the demand for prescription drugs, through policies (such as investment for basic research and regulations on what must be demonstrated in clinical trials) which affect the supply of new medicines, and through policies (such as vaccine recommendations) which affect both supply and demand. The surging R&D in the pharmaceutical industry worldwide is likely to improve the effectiveness of dystonia drugs and their utilization, thereby fueling the global market growth.

This report includes the key vendors operating in the market- Teva Pharmaceuticals Industries Ltd., F.Hoffmann-La Roche Ltd., Merz Pharma GmbH & Co. KGaA, Ipsen Pharma Biotech SAS, Hameln Pharma Gmbh (Siegfried Group, LLP), AbbVie, Inc., Amneal Pharmaceuticals, Inc., Wellona Pharma, Pfizer, Inc. and Novartis AG.

Henceforth, the dystonia drugs market is anticipated to witnessing a significant in the estimated time span. Since, compared to all treatments the drugs are considered to be the best option for the dystonia. The drugs are deemed to provide the quick and complete relief for the ailment.

This report of Dystonia Drugs market depicts the geographical regions and sub segment which is projected to have the rapid growth and having the major share.
This study implies the factors which are compelling and restricting the market growth and the providing pitfalls and opportunities for the Dystonia Drugs market.
This report also consists of information of the market’s leading vendors and their position in the market.
This report also consists of constant market developments and innovations taking place in the Dystonia Drugs

Additional information

User License	Single User, Multi User, Enterprise

Table Of Content

Executive Summary
Industry Outlook
- Industry Overview
- Industry Trends
Market Snapshot
- Market Definition
- Market Outlook
  - Porter Five Forces
- Related Markets
Market characteristics
- Market Overview
- Market Segmentation
- Market Dynamics
  - Drivers
  - Restraints
  - Opportunities
- DRO – Impact Analysis
Drug Type: Market Size & Analysis
- Overview
- Anticonvulsants drugs
- Others
- Dopaminergic agents
- GABAergic agents
Route of Administration: Market Size & Analysis
- Overview
- Oral
- Injectable
Distribution Channel: Market Size & Analysis
- Overview
- Hospital Pharmacies
- Online Providers
- Drug Stores and Retail Pharmacies
Geography: Market Size & Analysis
- Overview
- North America
- Europe
- Asia Pacific
- Rest of the World
Competitive Landscape
- Competitor Comparison Analysis
- Market Developments
  - Mergers and Acquisitions, Legal, Awards, Partnerships
  - Product Launches and execution

Vendor Profiles
- Teva Pharmaceuticals Industries Ltd.
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- Hoffmann-La Roche Ltd.
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- Merz Pharma GmbH & Co. KGaA
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- Ipsen Pharma Biotech SAS
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- Hameln Pharma Gmbh (Siegfried Group, LLP)
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- AbbVie, Inc.
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- Amneal Pharmaceuticals, Inc.
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- Wellona Pharma
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- Pfizer, Inc.
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- Novartis AG
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy

Analyst Opinion
Annexure
- Report Scope
- Market Definitions
- Research Methodology
  - Data Collation and In-house Estimation
  - Market Triangulation
  - Forecasting
- Report Assumptions
- Declarations
- Stakeholders
- Abbreviations

Methodology

Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:

Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary data bases and Models)
Market Triangulation
Forecasting

List of Tables

TABLE 1. GLOBAL DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 2. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR ANTICONVULSANTS DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 3. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 4. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR DOPAMINERGIC AGENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 5. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR GABAERGIC AGENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 6. GLOBAL DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 7. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR ORAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 8. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR INJECTABLE, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 9. GLOBAL DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 10. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 11. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 12. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR DRUG STORES AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 13. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 14. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 15. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 16. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 17. U.S DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 18. U.S DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 19. U.S DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 20. CANADA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 21. CANADA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 22. CANADA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 23. EUROPE DYSTONIA DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 24. EUROPE DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 25. EUROPE DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 26. EUROPE DYSTONIA DRUGS MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 27. GERMANY DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 28. GERMANY DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 29. GERMANY DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 30. U.K DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 31. U.K DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 32. U.K DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 33. FRANCE DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 34. FRANCE DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 35. FRANCE DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 36. ITALY DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 37. ITALY DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 38. ITALY DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 39. SPAIN DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 40. SPAIN DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 41. SPAIN DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 42. ROE DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 43. ROE DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 44. ROE DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 45. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 46. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 47. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 48. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 49. CHINA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 50. CHINA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 51. CHINA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 52. INDIA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 53. INDIA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 54. INDIA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 55. JAPAN DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 56. JAPAN DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 57. JAPAN DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 58. REST OF APAC DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 59. REST OF APAC DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 60. REST OF APAC DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 61. REST OF WORLD DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 62. REST OF WORLD DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 63. REST OF WORLD DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 64. TEVA PHARMACEUTICALS INDUSTRIES LTD.: FINANCIALS

TABLE 65. TEVA PHARMACEUTICALS INDUSTRIES LTD.: PRODUCTS & SERVICES

TABLE 66. TEVA PHARMACEUTICALS INDUSTRIES LTD.: RECENT DEVELOPMENTS

TABLE 67. F.HOFFMANN-LA ROCHE LTD.: FINANCIALS

TABLE 68. F.HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES

TABLE 69. F.HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS

TABLE 70. MERZ PHARMA GMBH & CO. KGAA: FINANCIALS

TABLE 71. MERZ PHARMA GMBH & CO. KGAA: PRODUCTS & SERVICES

TABLE 72. MERZ PHARMA GMBH & CO. KGAA: RECENT DEVELOPMENTS

TABLE 73. IPSEN PHARMA BIOTECH SAS: FINANCIALS

TABLE 74. IPSEN PHARMA BIOTECH SAS: PRODUCTS & SERVICES

TABLE 75. IPSEN PHARMA BIOTECH SAS: RECENT DEVELOPMENTS

TABLE 76. HAMELN PHARMA GMBH (SIEGFRIED GROUP, LLP): FINANCIALS

TABLE 77. HAMELN PHARMA GMBH (SIEGFRIED GROUP, LLP): PRODUCTS & SERVICES

TABLE 78. HAMELN PHARMA GMBH (SIEGFRIED GROUP, LLP): RECENT DEVELOPMENTS

TABLE 79. ABBVIE, INC.: FINANCIALS

TABLE 80. ABBVIE, INC.: PRODUCTS & SERVICES

TABLE 81. ABBVIE, INC.: RECENT DEVELOPMENTS

TABLE 82. AMNEAL PHARMACEUTICALS, INC.: FINANCIALS

TABLE 83. AMNEAL PHARMACEUTICALS, INC.: PRODUCTS & SERVICES

TABLE 84. AMNEAL PHARMACEUTICALS, INC.: RECENT DEVELOPMENTS

TABLE 85. WELLONA PHARMA: FINANCIALS

TABLE 86. WELLONA PHARMA: PRODUCTS & SERVICES

TABLE 87. WELLONA PHARMA: RECENT DEVELOPMENTS

TABLE 88. PFIZER, INC.: FINANCIALS

TABLE 89. PFIZER, INC.: PRODUCTS & SERVICES

TABLE 90. PFIZER, INC.: RECENT DEVELOPMENTS

TABLE 91. NOVARTIS AG: FINANCIALS

TABLE 92. NOVARTIS AG: PRODUCTS & SERVICES

TABLE 93. NOVARTIS AG: RECENT DEVELOPMENTS